Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study

References

• World Health Organization. Medicines and health products, Pharmacovigilance. [cited 2016 Aug 20]. Available from: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
   Google Scholar
• Ministry of Health and China Food and Drug Administration. The Adverse Drug Reaction Reporting and Monitoring Provision (The Ministry of Health Decree 81), May 2011. [cited 2016 Aug 20]. http://www.sda.gov.cn/WS01/CL0053/62621_7.html
   Google Scholar
• Aagaard L, Strandell J, Melskens L, et al. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012;35(12):1171–1182.
   PubMed Web of Science ®Google Scholar
• Wise L, Parkinson J, Raine J, et al. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov. 2009;8(10):779–782.
   PubMed Web of Science ®Google Scholar
• Scott HD, Thacher-Renshaw A, Rosenbaum SE, et al. Physician reporting of adverse drug reactions. JAMA. 1990;263(13):1785–1788.
   PubMed Web of Science ®Google Scholar
• Van Grootheest K. The dawn of pharmacovigilance: an historical perspective. Int J Pharm Med. 2003. DOI:10.2165/00124363-200317050-00006
   Google Scholar
• World Health Organization. The uppsala monitoring center, VigiBase. [cited 2016 Jan 5]. Available from: http://www.whoumc.org/DynPage.aspx?id=98082&mn1=7347&mn2=7252&mn3=7322&mn4=7326
   Google Scholar
• Zhang L. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37:765–770.
   PubMed Web of Science ®Google Scholar
• The Standing Committee of the National People’s Congress of the People’s Republic of China ’The pharmaceutical administration law of the People’s Republic of China (Presidential Decree 45), Feb 2001. [cited 2016 Aug 20]. Available from: http://www.sda.gov.cn/WS01/CL0064/23396.html
   Google Scholar
• China Food and Drug Administration (CFDA). Annual ADR report on national ADR monitoring, Jul 2016. [cited 2016 Aug 20]. Available from: http://www.sda.gov.cn/WS01/CL0053/62621_7.html
   Google Scholar
• Shao R, Tang JF. The effect evaluation of adverse drug reaction monitoring system in China. Chin J Health Policy. 2014;7(8):29–36.
   Google Scholar
• Jiao XU, Wang Z, Shen HQ, et al. Discussion on the problems and countermeasures of adverse drug reactions monitoring in China. China Pharm. 2013;18:1693–1696.
   Google Scholar
• Guo XJ, Ye XF, Wang XX, et al. Reporting patterns of adverse drug reactions over recent years in China: analysis from publications. Expert Opin Drug Saf. 2015;14(2):191–198.
   PubMed Web of Science ®Google Scholar
• Zhu L, Huang P, Monitoring Status LY. Existing problems of adverse drug reaction in China. Chin Pharm Aff. 2017;30(7):729–734.
   Google Scholar
• Olsson S, Pal SN, Stergachis A, et al. Pharmacovigilance activities in 55 low- and middle-income countries. Drug Saf. 2010;33:689–703.
   PubMed Web of Science ®Google Scholar
• Strengthening Pharmaceutical Systems (SPS). Indicator-based pharmacovigilance assessment tool: manual for conducting assessments in developing countries. Submitted to the U.S. Agency for international development by the SPS program. Arlington, VA: Management Sciences for Health; 2009.
   Google Scholar
• Agoro OO, Kibira SW, Freeman JV, et al. Barriers to the success of an electronic pharmacovigilance reporting system in Kenya: an evaluation three years post implementation. J Am Med Inform Assoc. 2017;25:627-634.
   Web of Science ®Google Scholar
• Khan TM Community pharmacists’ knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, SaudiArabia. Ther Adv Drug Saf. 2013; 4:45–51.
   PubMedGoogle Scholar
• Alraie NA, Saad AA, Sabry NA, et al. Adverse drug reactions reporting: a questionnaire-based study on Egyptian pharmacists’ attitudes following an awareness workshop. J Eval Clin Pract. 2015;22(3):349–355.
   PubMed Web of Science ®Google Scholar
• Dweik RA, Stacey D, Kohen D, et al. Factors affecting patients reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2017;83(4):875–883.
   PubMed Web of Science ®Google Scholar
• Gurmesa LT, Dedefo MG Factors affecting adverse drug reaction reporting of healthcare professionals and their knowledge, attitude, and practice towards ADR reporting in Nekemte Town, West Ethiopia. Biomed Res Int. 2016;2016(4):1–6.
   Google Scholar
• Su C, Ji H, Su Y. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010;19(3):217–222.
   PubMed Web of Science ®Google Scholar
• Feely J, Moriarty S, O’Connor P. Stimulating reporting of adverse drug reactions by using a fee. BMJ. 1990;300(6716):22–23.
   PubMed Web of Science ®Google Scholar
• Bäckström M, Mjörndal T A small economic inducement to stimulate increased reporting of adverse drug reactions—a way of dealing with an old problem? Eur J Clin Pharmacol, 2006; 62(5):381.
   PubMed Web of Science ®Google Scholar
• Feng C, Yue XM, Jie ZM, et al. A time series analysis of the effects of financial incentives and mandatory clinical applications as interventions to improve spontaneous adverse drug reaction reporting by hospital medical staff in China. J Eval Clin Pract. 2017;23:1316–1321.
   PubMed Web of Science ®Google Scholar
• Elshafie S, Zaghloul I, Roberti AM Pharmacovigilance in developing countries (part I): importance and challenges. Int J Clin Pharm, 2017;7:1-6.
   PubMedGoogle Scholar
• Pirmohamed M, Atuah KN, Dodoo AN, et al. Pharmacovigilance in developing countries; Requires collaboration between stakeholders to develop novel models of funding. BMJ 2007; 335:462.
   PubMed Web of Science ®Google Scholar
• Elkalmi RM, Hassali MA, Ibrahim MI, et al. Community pharmacists’ attitudes, perceptions, and barriers toward adverse drug reaction reporting in Malaysia: a quantitative insight. J Patient Saf. 2014;10(2):81–87.
   PubMed Web of Science ®Google Scholar
• Wang YH. Study on the adverse drug reaction monitoring mode Chinese trend. China Health Stand Manag. 2017;24(8):87–89.
   Google Scholar
• Ke-Ren T, Jing G, Jian M. Analysis of adverse drug reaction monitoring and inspection system for drug manufacturers in our province. Chin J Pharmacovigilance. 2014;5(11):285–287.
   Google Scholar
• Huff-Rousselle M, Simooya O, Kabwe V, et al. Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond. Glob Public Health. 2007; 2(2):184–203.
   PubMedGoogle Scholar
• Rolfes L, Van HF, Van D LL, et al. The quality of clinical information in adverse drug reaction reports by patients and healthcare professionals: a retrospective comparative analysis. Drug Saf. 2017;40(7):1–8.
   PubMed Web of Science ®Google Scholar
• Banovac M, Candore G, Slattery J, et al. Patient reporting in the EU: analysis of EudraVigilance data. Drug Saf. 2017;40(7):1–17.
   PubMed Web of Science ®Google Scholar
• Wu SF, Wang L, Li YJ, et al. Research on the public reporting model for adverse drug reactions in China. Chin J Pharmacovigilance. 2017;14(7):407–412.
   Google Scholar
• Lu CF, Cui XK, Liu WW, et al. Exploration on the model of provincial ADR monitoring support the drug supervision. Chin J Pharmacovigilance. 2018;15(1):24–27.
   Google Scholar
• Hou Y, Li X, Wu G, et al. National ADR Monitoring System in China. Drug Saf. 2016;39(11):1043–1051.
   PubMed Web of Science ®Google Scholar